Evotec SE
EVO
查看详细走势图
3.130USD
-0.010-0.32%
收盘 12/24, 13:00（美东）报价延迟15分钟
1.11B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-0.32%
5天
+6.46%
1月
+3.30%
6月
-23.28%
今年开始到现在
-24.76%
1年
-37.40%
查看详细走势图
TradingKey Evotec SE股票评分
单位: USD 更新时间: 2025-12-24操作建议
Evotec SE当前公司基本面数据相对健康，增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名145/404位。机构持股占比非常高，近一月多位分析师给出公司评级为持有。最高目标价5.00。中期看，股价处于下降通道。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Evotec SE评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
3
位分析师
持有
评级
5.000
目标均价
+66.11%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Evotec SE亮点
亮点风险
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Evotec SE新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Evotec SE简介
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
公司代码EVO
公司Evotec SE
CEOWojczewski (Christian)
网址https://www.evotec.com/
常见问题
Evotec SE(EVO)的当前股价是多少？
Evotec SE(EVO)的当前股价是 3.130。
Evotec SE的股票代码是什么？
Evotec SE的股票代码是EVO。
Evotec SE股票的52周最高点是多少？
Evotec SE股票的52周最高点是5.100。
Evotec SE股票的52周最低点是多少？
Evotec SE股票的52周最低点是2.840。
Evotec SE的市值是多少？
Evotec SE的市值是1.11B。
Evotec SE的净利润是多少？
Evotec SE的净利润为-212.07M。
现在Evotec SE(EVO)的股票是买入、持有还是卖出？
根据分析师评级，Evotec SE(EVO)的总体评级为持有，目标价格为5.000。
Evotec SE(EVO)股票的每股收益（EPS TTM）是多少
Evotec SE(EVO)股票的每股收益（EPS TTM）是-0.493。
相关品种
